文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

oXiris与常规连续肾脏替代治疗在严重腹腔感染中的比较:对感染性休克死亡率的影响

COMPARISON OF OXIRIS AND CONVENTIONAL CONTINUOUS RENAL REPLACEMENT THERAPY IN MANAGING SEVERE ABDOMINAL INFECTIONS: IMPACT ON SEPTIC SHOCK MORTALITY.
PubMed 文献 · Shock · 2024-08-14
一句话结论回顾性分析显示,oXiris较常规CRRT降低严重腹腔感染14天死亡率(24.4% vs 43.6%),28天死亡率无显著差异,多因素回归示oXiris与14天、28天死亡率分别降低71.3%和67.6%相关。

该研究为福建医科大学附属第一医院重症医学科2017至2023年的回顾性分析,比较oXiris与常规CRRT治疗严重腹腔感染的效果。oXiris组在24小时即出现心率、平均动脉压、乳酸、氧合指数、中性粒细胞比值、IL-6及APACHE II、SOFA评分改善;72小时除血小板外各指标均改善。oXiris组14天死亡率24.4%,显著低于常规组43.6%,28天死亡率两组无显著差异。多因素logistic回归显示oXiris治疗与14天、28天死亡率分别降低71.3%和67.6%相关。

要点

  • oXiris组14天死亡率24.4%,常规CRRT组43.6%,差异显著;28天死亡率两组无显著差异。
  • 多因素logistic回归显示,oXiris治疗与严重腹腔感染14天死亡率降低71.3%、28天死亡率降低67.6%相关。
  • oXiris组24小时即出现心率、平均动脉压、乳酸、氧合指数、中性粒细胞比值、IL-6改善,APACHE II和SOFA评分下降。
  • 常规CRRT组24小时仅乳酸较治疗前改善;72小时心率、乳酸、CRP、IL-6改善。
  • 72小时两组指标变化值比较,除降钙素原外,oXiris组改善更显著。

适用人群与场景

  • 2017至2023年福建医科大学附属第一医院重症医学科收治的严重腹腔感染患者,分为oXiris组和常规CRRT组。

研究设计与关键结果

  • 研究类型:回顾性分析,地点为福建医科大学附属第一医院重症医学科,时间2017至2023年,比较oXiris与常规CRRT治疗严重腹腔感染。
  • 常规CRRT组:治疗24小时较治疗前仅乳酸水平显著改善;治疗72小时心率、乳酸、CRP、IL-6改善。
  • oXiris组:治疗24小时较基线心率、平均动脉压、乳酸、氧合指数、中性粒细胞比值、IL-6改善,APACHE II和SOFA评分下降;治疗72小时除血小板计数外所有参数改善。
  • 两组24小时指标变化值(Δ)在心率、平均动脉压、乳酸、去甲肾上腺素剂量、CRP、IL-6、APACHE II评分、SOFA评分存在差异。
  • 72小时Δ指标显示,除降钙素原外,oXiris组改善更显著。
  • oXiris组14天死亡率24.4%,常规组43.6%,oXiris组显著降低;28天死亡率两组无显著差异。
  • 多因素logistic回归分析显示,oXiris治疗与严重腹腔感染14天和28天死亡率分别降低71.3%和67.6%相关。

证据类型、等级与局限

  • 证据类型:回顾性分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,oXiris在严重腹腔感染管理中较常规CRRT显示出明确优势,可降低病死率,是一种有前景且有效的治疗选择。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Objective: The objective of this study is to assess and compare the efficacy of oXiris with conventional continuous renal replacement therapy (CRRT) in managing severe abdominal infections. Methods: A retrospective analysis encompassing cases from 2017 to 2023 was conducted at the Department of Critical Care Medicine within the First Affiliated Hospital of Fujian Medical University. Parameters including heart rate (HR), mean arterial pressure (MAP), oxygenation index, lactate (Lac), platelet count, neutrophil ratio, procalcitonin, C-reactive protein (CRP), interleukin 6 (IL-6), norepinephrine dosage, Acute Physiology and Chronic Health Evaluation II (APACHE II), and Sequential Organ Failure Assessment (SOFA) were recorded prior to treatment initiation, at 24 h, and 72 h after treatment for both the oXiris and conventional CRRT groups. In addition, the duration of respiratory support, CRRT treatment, length of stay in the intensive care unit (ICU), total hospitalization period, and mortality rates at 14 and 28 days for both groups were recorded. Results: 1) Within the conventional CRRT group, notable enhancement was observed solely in Lac levels at 24 h after treatment compared with pretreatment levels. In addition, at 72 h after treatment, improvements were evident in HR, Lac, CRP, and IL-6 levels. 2) Conversely, the oXiris group exhibited improvements in HR, MAP, Lac, oxygenation index, neutrophil ratio, and IL-6 at 24 h after treatment when compared with baseline values. In addition, reductions were observed in APACHE II and SOFA scores. At 72 h after treatment, all parameters demonstrated enhancement except for platelet count. 3) Analysis of the changes in the indexes (Δ) between the two groups at 24 h after treatment revealed variances in HR, MAP, Lac, norepinephrine dosage, CRP levels, IL-6 levels, APACHE II scores, and SOFA scores. 4) The Δ indexes at 72 h after treatment indicated more significant improvements following oXiris treatment for both groups, except for procalcitonin. 5) The 14-day mortality rate (24.4%) exhibited a significant reduction in the oXiris group when compared with the conventional group (43.6%). However, no significant difference was observed in the 28-day mortality rate between the two groups. 6) Subsequent to multifactorial logistic regression analysis, the results indicated that oXiris treatment correlated with a noteworthy decrease in the 14-day and 28-day mortality rates associated with severe abdominal infections, by 71.3% and 67.6%, respectively. Conclusion: oXiris demonstrates clear advantages over conventional CRRT in the management of severe abdominal infections. Notably, it reduces the fatality rates, thereby establishing itself as a promising and potent therapeutic option.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Liao XY, Chen YT, Liu MJ, et al. COMPARISON OF OXIRIS AND CONVENTIONAL CONTINUOUS RENAL REPLACEMENT THERAPY IN MANAGING SEVERE ABDOMINAL INFECTIONS: IMPACT ON SEPTIC SHOCK MORTALITY. Shock. 2024. PMID: 39158926. doi:10.1097/SHK.0000000000002437

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。